Xeris Biopharma Holdings
XERS
110 hedge funds and large institutions have $102M invested in Xeris Biopharma Holdings in 2023 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 36 increasing their positions, 25 reducing their positions, and 9 closing their positions.
1,210% more call options, than puts
Call options by funds: $1.73M | Put options by funds: $132K
89% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 9
44% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 25
8% more funds holding
Funds holding: 102 → 110 (+8)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.88% less ownership
Funds ownership: 40.73% → 39.85% (-0.88%)
30% less capital invested
Capital invested by funds: $147M → $102M (-$44.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$1.5M |
| 2 |
Millennium Management
New York
|
+$1.06M |
| 3 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$951K |
| 4 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$893K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$797K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$4.09M |
| 2 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$4.01M |
| 3 |
EI
EAM Investors
Solana Beach,
California
|
-$1.99M |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$574K |
| 5 |
Tudor Investment Corp
Stamford,
Connecticut
|
-$497K |
XERS Hedge Fund Activity: Q3 2023 in Review
110 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Xeris Biopharma Holdings (XERS) for Q3 2023, worth a combined $102M — down 30% from $147M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new XERS positions and 9 closed out — a net gain of 8 holders — while 36 added to existing stakes and 25 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $1.5M. The largest seller was Invesco, cutting an estimated $4.09M.
- 110 institutional investors held Xeris Biopharma Holdings (XERS) as of Q3 2023, up from 102 in Q2 2023.
- Funds reported $102M of Xeris Biopharma Holdings stock for Q3 2023, down 30% quarter-over-quarter.
- 17 funds opened new Xeris Biopharma Holdings positions in Q3 2023 and 9 closed out, a net change of +8 holders.
- The largest Xeris Biopharma Holdings buyer in Q3 2023 was Point72 Asset Management, an estimated $1.5M added.
- The largest Xeris Biopharma Holdings seller in Q3 2023 was Invesco, an estimated $4.09M sold.
Based on aggregated 13F filings for Q3 2023.